- Home
- XRTX vs NUWE Comparison
XRTX vs NUWE Comparison
Compare XRTX & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRTX | NUWE |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.2M |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | XRTX | NUWE |
|---|---|---|
| Price | $0.97 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 346.0K | 126.5K |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,270,000.00 |
| Revenue This Year | N/A | $19.32 |
| Revenue Next Year | $392.31 | $12.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.41 |
| 52 Week High | $3.60 | $24.70 |
Technical Indicators
Market Signals| Indicator | XRTX | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 28.81 | 28.38 |
| Support Level | $0.37 | $0.43 |
| Resistance Level | $2.26 | $1.46 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 2.73 | 10.83 |
Price Performance
Historical ComparisonAbout XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
About NUWE Nuwellis Inc.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.